MUSC The Catalyst
MUSC arial view


MUSCMedical LinksCharleston LinksArchivesCatalyst AdvertisersSeminars and EventsResearch StudiesPublic RelationsResearch GrantsCatalyst PDF FileMUSC home pageCommunity HappeningsCampus NewsApplause

MUSCMedical LinksCharleston LinksArchivesCatalyst AdvertisersSeminars and EventsResearch StudiesPublic RelationsResearch GrantsMUSC home pageCommunity HappeningsCampus NewsApplause


Darvon may be in jeopardy

by Mary Helen Yarborough
Public Relations
The narcotic pain killer Darvon may no longer be available to patients if the Food and Drug Administration agrees with the recommendation by two of its advisory committees to ban it.
Based on reports citing a high incidence of fatal or serious overdoses, the FDA’s Anesthetic and Life Support Drugs Advisory and the Drug Safety and Risk Management Advisory committees voted in a special joint meeting on Jan. 30 to ban the drug, and products containing propoxyphene (Darvon and Darvocet) from the U.S. market. It was withdrawn in Great Britain in 2005.
The advisory panels agreed to gradually withdraw the drug, which has been available since 1957, to enable the large numbers of those prescribed to it to transition to another therapy.
Darvon is the third most widely-used narcotic pain killer behind hydrocodone and oxycodone.
Arthur Rick Smith, M.D., assistant professor of anesthesia & perioperative medicine, and pain management expert, said that propoxyphene has a history of controversy, including whether the relatively mild opioid is much stronger than acetaminophen.
“Studies have shown that it may not be any stronger than Tylenol or aspirin,” Smith said. “On the other hand, there are some patients that find using it helpful for their chronic pain, and it is still prescribed a fair amount. Like all drugs, there is a risk/benefit ratio, balancing the toxicity against the positive effects. With all opioids one of the most important toxicities is overdose and respiratory depression, and this is true of propoxyphene as well.”
Propoxyphene also is cardiotoxic, meaning that abusing it can cause dangerous cardiac rhythm changes.
“The result is that the safety margin between the effective and toxic dosages for this drug is narrower than many other pain medications,” Smith said. “Alternatives to propoxyphene include acetaminophen, aspirin, nonsteroidal anti-inflammatory drugs like ibuprofen, or low doses of other opioids.”
Treatment options for chronic pain vary, including the use of many different types of medications, therapies, interventions and surgeries, Smith said.


Friday, March 27, 2009

The Catalyst Online is published weekly by the MUSC Office of Public Relations for the faculty, employees and students of the Medical University of South Carolina. The Catalyst Online editor, Kim Draughn, can be reached at 792-4107 or by email, Editorial copy can be submitted to The Catalyst Online and to The Catalyst in print by fax, 792-6723, or by email to To place an ad in The Catalyst hardcopy, call Island Publications at 849-1778, ext. 201.